India s pharmaceutical market saw a 9.5% growth in March, reaching 16,158 crore in sales. The Moving Annual Total reached 197,976 crore with a 6.5% growth rate, with cardiology and anti-infectives among the top performers.
American pharma major Eli Lilly sees India as its launchpad for a new growth trajectory, using its new drugs for diabetes and obesity as the fuel. Will this strategic pivot work? - Issue Date: Mar 31, 2024
The Indian pharmaceutical market (IPM) saw a robust growth of 9.5% in January with all major therapy areas recording double-digit growth. According to market research firm Pharmarack, a majority of the top 10 therapy areas, including cardiac, anti-infectives, and gastrointestinal, showed double-digit value growth. Respiratory, pain/analgesics, urology, antineoplastics, and stomatologicals also saw higher unit growth.
India ranks 126th out of 146 countries in the World Happiness Index, indicating low levels of happiness. The decline has been attributed to the mental health crisis in the country, worsened by the Covid-19 pandemic. Sales of antidepressants and mood stabilizers have seen a significant increase, with a 41% surge in India and a 35% rise in Gujarat. The overall sale of drugs related to neurological and central nervous system therapy has also increased by 28%.